PTC THERAPEUTICS, INC.
PTCT evidence brief
What we can confirm
- BioSniper Score:
- 3.8 / 10
- Market Cap:
- $5.74B
- Lead Asset:
- Upstaza (Approved)
What it means
What to watch
Prepared research question
What matters most for PTCT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PTCT
PTC Therapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for rare and neurological disorders, with approved products including Sephience for PKU and a pipeline spanning gene therapy and small molecules.
Key risk: Vatiquinone regulatory delay
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 20 clinical trials · 1 catalyst for PTC THERAPEUTICS, INC..
PTC Therapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for rare and neurological disorders, with approved products including Sephience for PKU and a pipeline spanning gene therapy and small molecules.
- Reported total revenue of $360.5M and net income of $83.5M for the six months ended June 30, 2026 [sec].
- Cash and equivalents of $1,049.9M as of June 30, 2026, with shareholders' equity of -$165.4M and total debt of $591.0M [sec].
- Sephience (for PKU) generated $111.2M in net revenue in 2025 following global regulatory approvals in the U.S., EU, and Japan [sec · filed 2026-04-20].
- Phase 2 PIVOT-HD study of votoplam met its primary endpoint of reduction in blood Huntingtin protein levels at week 12 [sec · filed 2026-04-20].
- A rolling BLA submission for ST-920 (gene therapy) is expected to be completed in Q4 2026 [sec · filed 2026-08-13].
What works
- Strong commercial execution: Sephience generated $111.2M in net revenue in its first year of launch, and total 2025 product/royalty revenue of $830.9M exceeded guidance [sec · filed 2026-04-20].
- Multiple regulatory approvals achieved for Sephience in the U.S., EU, and Japan, demonstrating global regulatory capability [sec · filed 2026-04-20].
- Late-stage pipeline advancing: vatiquinone for Friedreich's ataxia is proceeding to a new Phase 2/3 study (PROVE-FA) in Q3 2026, and ST-920 BLA submission is on track for Q4 2026 [sec · filed 2026-08-13][sec_mda · as of 2026-07-30].
What to weigh
- Negative shareholders' equity of -$165.4M as of June 30, 2026, indicating accumulated deficits exceed equity [sec].
- Vatiquinone NDA for Friedreich's ataxia was not accepted by FDA, requiring an additional study (PROVE-FA) to support resubmission, delaying potential approval [sec_mda · as of 2026-07-30].
- Operating expenses remain high: 2025 GAAP R&D plus SG&A was $802.4M, and the company notes that drug development is 'highly uncertain' with numerous risks [sec · filed 2026-04-20][sec_mda · as of 2026-07-30].
- Total debt of $591.0M as of June 30, 2026, represents a significant financial obligation [sec].
From the filings
Quoted directly from source documents.
Sephience generated $111.2M in net revenue in 2025
“The global launch of Sephience, including total net revenue of $111.2 million in 2025”
SEC filings · April 20, 2026
Vatiquinone requires an additional study for NDA resubmission
“the FDA suggested an additional study be conducted to support NDA resubmission”
SEC MD&A · July 30, 2026
ST-920 BLA submission expected in Q4 2026
“A rolling biologics license application ("BLA") submission to FDA for accelerated approval of ST-920 is expected to be completed in the fourth quarter of 2026”
SEC filings · August 13, 2026
Phase 2 PIVOT-HD met primary endpoint
“Phase 2 PIVOT-HD study of votoplam met primary endpoint of reduction in blood Huntingtin protein levels at week 12”
SEC filings · April 20, 2026
Catalyst timeline
- 2031-04-29 · Patent_Expiry · INOTERSEN SODIUM — Patent expiry for NDA211172 (INOTERSEN SODIUM) may open the door for generic competition, potentially impacting revenue from that product.
Risks & what to watch (4)›
Key risks
- Vatiquinone regulatory delay — FDA required an additional study (PROVE-FA) for vatiquinone NDA resubmission, pushing potential approval timeline [sec_mda · as of 2026-07-30]
- Negative shareholders' equity — Shareholders' equity of -$165.4M as of June 30, 2026 indicates accumulated losses exceed equity [sec]
- High operating expenses — 2025 GAAP R&D plus SG&A was $802.4M, and expenses are expected to increase with new trials and launches [sec · filed 2026-04-20]
- Debt burden — Total debt of $591.0M as of June 30, 2026 represents a significant financial obligation [sec]
What to watch
- Initiation of the PROVE-FA study for vatiquinone in Q3 2026 and its impact on NDA resubmission [sec_mda · as of 2026-07-30]
- Completion of the rolling BLA submission for ST-920 in Q4 2026 and potential FDA accelerated approval [sec · filed 2026-08-13]
- Sephience revenue trajectory and global market expansion following its 2025 launch [sec · filed 2026-04-20]
- Patent expiry of INOTERSEN SODIUM on 2031-04-29, which may affect related product revenue [catalyst]
Sources: Catalysts · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run PTC THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PTC THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
Net income $83M
Lead: Approved
1 candidate
1 upcoming, next in ~1658d
0 buys · 61 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
349
Total value held
$6.35B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 12,948,717 | $882.2M |
| rtw investments, lp | 7,746,415 | $527.8M |
| janus henderson group plc | 7,193,433 | $490.0M |
| vanguard portfolio management llc | 4,804,594 | $327.3M |
| state street corp | 4,346,519 | $296.1M |
| wellington management group llp | 3,942,610 | $268.6M |
| vanguard capital management llc | 3,676,256 | $250.5M |
| toronto dominion bank | 3,025,963 | $206.2M |
| geode capital management, llc | 2,209,954 | $150.6M |
| armistice capital, llc | 2,074,449 | $141.3M |
Showing top 10 of 349 institutional holders of PTC THERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 13.0%
- Days to cover
- 7.8
- Shares short
- 9,452,081
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PTCT short interestGovernance
Frequently asked questions
What is the AI investment thesis for PTC THERAPEUTICS, INC.?
PTC Therapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for rare and neurological disorders, with approved products including Sephience for PKU and a pipeline spanning gene therapy and small molecules.
What is PTC THERAPEUTICS, INC.'s lead drug candidate?
PTC THERAPEUTICS, INC.'s most advanced tracked candidate is Upstaza (Approved) for Aromatic L-Amino Decarboxylase (AADC) deficiency.
What is PTC THERAPEUTICS, INC.'s next catalyst?
PTC THERAPEUTICS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA211172" — expected April 29, 2031.
Who is the CEO of PTC THERAPEUTICS, INC.?
Dr. Matthew B. Klein F.A.C.S., M.D., M.S. is the chief executive officer of PTC THERAPEUTICS, INC. (PTCT).
Where is PTC THERAPEUTICS, INC. headquartered?
PTC THERAPEUTICS, INC. (PTCT) is headquartered in Warren, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.